Ibio, Inc. balance sheet IBIO

Annual Quarterly

As of Jun 30, 2026, Ibio, Inc. had total assets of $99.1 million and total liabilities of $13.4 million. Total assets were up 327.5% from a year earlier. Stockholders' equity was $85.7 million. It held $88.0 million in cash and investments against $2.2 million of total debt, net cash of $85.8 million. The current ratio, current assets divided by current liabilities, was 7.85.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Jun 30, 2025
FY 2024
Jun 30, 2024
FY 2023
Jun 30, 2023
FY 2022
Jun 30, 2022
FY 2021
Jun 30, 2021
FY 2020
Jun 30, 2020
FY 2019
Jun 30, 2019
FY 2018
Jun 30, 2018
FY 2017
Jun 30, 2017
Assets
Cash
56
+557.1%
9
-39.6%
14
+230.4%
4
-81.0%
23
-70.7%
77
+40.4%
55
+1146.6%
4
+0.0%
4
-72.3%
16
+0.0%
Short-term investments
32
—
—
—
—
—
—
—
—
—
Cash and investments
88
+925.9%
9
-39.6%
14
+230.4%
4
-81.0%
23
-70.7%
77
+40.4%
55
+1146.6%
4
+0.0%
4
-72.3%
16
+0.0%
Receivables
—
—
0
0
1
+134.7%
0
+468.0%
0
-22.7%
0
+29.3%
0
-57.1%
0
-63.8%
Inventory
—
—
0
-100.0%
—
4
—
—
—
—
—
Total current assets
92
+848.7%
10
-38.0%
16
-40.3%
26
-41.7%
45
-56.9%
105
+69.4%
62
+1184.3%
5
-70.5%
16
+90.0%
9
-64.1%
Property and equipment, net
3
-2.4%
3
-12.9%
4
-13.9%
4
+207.3%
1
-84.1%
9
+135.9%
4
-85.0%
24
-3.1%
25
-1.7%
26
+0.1%
Total assets
99
+327.5%
23
-19.3%
29
-30.3%
41
-58.5%
99
-32.4%
147
+56.0%
94
+207.9%
31
-29.0%
43
+19.6%
36
-30.2%
Liabilities and equity
Accounts payable
4
+102.1%
2
+511.2%
0
-80.6%
2
-56.6%
4
+89.2%
2
+28.1%
2
+75.7%
1
+26.7%
1
+5.5%
1
-36.4%
Total current liabilities
12
+92.4%
6
+59.0%
4
-82.6%
22
-27.4%
30
+358.0%
7
+26.9%
5
+51.4%
3
+69.9%
2
+1.1%
2
-12.1%
Total liabilities
13
+61.3%
8
+12.1%
7
-71.3%
26
-28.1%
36
-6.5%
38
+2.2%
38
+33.6%
28
+4.5%
27
-0.6%
27
-1.7%
Stockholders' equity
86
+476.0%
15
-30.2%
21
+38.6%
15
-75.8%
63
-41.5%
109
+91.8%
57
+2198.7%
2
-84.8%
16
+81.4%
9
-10.3%
Debt
Lease liabilities
2
-19.8%
3
-19.9%
3
-16.0%
4
+12.4%
4
-88.5%
32
-0.6%
32
—
—
—
Total debt
2
-19.8%
3
-19.9%
3
-16.0%
4
+12.4%
4
-88.5%
32
-0.6%
32
—
—
—
Net cash
86
+1369.9%
6
-45.9%
11
+6445.1%
0
-99.1%
19
-58.1%
45
+98.6%
23
—
—
—
Ratios
Current ratio
7.85x
1.59x
4.08x
1.19x
1.48x
15.74x
11.79x
1.39x
8.00x
4.26x
Debt to equity
0.03x
0.18x
0.16x
0.27x
0.06x
0.30x
0.57x
—
—
—
Return on equity
-38.55%
-123.50%
-116.80%
—
-79.24%
-21.37%
-29.03%
-714.29%
-99.62%
-163.02%
Return on assets
-33.34%
-79.26%
-86.68%
—
-50.60%
-15.79%
-17.45%
-57.52%
-37.38%
-40.36%
Book value per share
1.54
0.77
2.47
15.15
7.27
12.46
0.40
0.12
1.01
1.00
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
IBIO (Nasdaq)
Fiscal year ends
June 30
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1420720
Former names
iBio, Inc. (until Oct 19, 2026); iBioPharma, Inc. (until Aug 14, 2009); InB:Biotechnologies, Inc. (until Jul 17, 2008)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.